Thailand's move to expand its generic drug program has jolted the pharmaceutical sector, but has also sparked fears among investors that the government could now change the rules for other industries, analysts said.
The army-installed government decided last month to allow imports of cheaper, copycat versions of a top-selling heart disease drug and an AIDS drug from India.
The move was hailed by charity Doctors Without Borders as an encouraging precedent for developing countries. Thailand offers universal health care and has been credited by the UN as having one of the best anti-AIDS programs.
Pharmaceutical firms have voiced outrage but some economists said the impact could reach beyond the drug industry.
"This is not just for pharmaceutical companies, but other investors outside the pharmaceutical industry see this and wonder whether the investment environment in Thailand is changing for [the] worse," said Bob Broadfoot, managing director of the Political and Economic Risk Consultancy in Hong Kong.
"They are worried this could happen to their industries," he said, adding that major foreign-owned businesses such as car makers and electronics firms have also become worried about the government's recent policy shifts.
Since the September coup the junta has made a host of miscues, including currency rules that have battered the stock market, leaving investors weary of its economic management.
"Foreign [business] communities in Thailand have been trying to have a dialogue with the government for months on issues like the generic drugs, but the government is not listening. I don't know why," Broadfoot said.
Thailand's top pharmaceutical industry group warned it might take legal action.
"It was a quite big shock to us. The decision was made unilaterally without any consultation," said Teera Chakajnarodom, president of the Pharmaceutical Research and Manufacturers' Association of Thailand. "Since this government is not elected, they may think that they can do whatever drastic things they want."
Teera expected the government to break the patents of an additional 11 drugs, including treatments for AIDS and cancer. The health ministry declined to confirm Teera's claim, but said its action was legal under the WTO.
But Albin Liew, a senior economist at United Overseas Bank, in Singapore, said foreign businesses outside the pharmaceutical industry were worried about how the issue was handled.
"The motive for their action is good, but the decision was made so unilaterally. Now big industries like auto, high-tech and textiles are concerned about sudden changes of business rules," Liew said.
Zhang Yazhou was sitting in the passenger seat of her Tesla Model 3 when she said she heard her father’s panicked voice: The brakes do not work. Approaching a red light, her father swerved around two cars before plowing into a sport utility vehicle and a sedan, and crashing into a large concrete barrier. Stunned, Zhang gazed at the deflating airbag in front of her. She could never have imagined what was to come: Tesla Inc sued her for defamation for complaining publicly about the vehicles brakes — and won. A Chinese court ordered Zhang to pay more than US$23,000 in
‘LEGACY CHIPS’: Chinese companies have dramatically increased mature chip production capacity, but the West’s drive for secure supply chains offers a lifeline for Taiwan When Powerchip Technology Corp (力晶科技) entered a deal with the eastern Chinese city of Hefei in 2015 to set up a new chip foundry, it hoped the move would help provide better access to the promising Chinese market. However, nine years later, that Chinese foundry, Nexchip Semiconductor Corp (合晶集成), has become one of its biggest rivals in the legacy chip space, leveraging steep discounts after Beijing’s localization call forced Powerchip to give up the once-lucrative business making integrated circuits for Chinese flat panels. Nexchip is among Chinese foundries quickly winning market share in the crucial US$56.3 billion industry of so-called legacy
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday held its first board of directors meeting in the US, at which it did not unveil any new US investments despite mounting tariff threats from US President Donald Trump. Trump has threatened to impose 100 percent tariffs on Taiwan-made chips, prompting market speculation that TSMC might consider boosting its chip capacity in the US or ramping up production of advanced chips such as those using a 2-nanometer technology process at its Arizona fabs ahead of schedule. Speculation also swirled that the chipmaker might consider building its own advanced packaging capacity in the US as part
‘NO DISRUPTION’: A US trade association said that it was ready to work with the US administration to streamline the program’s requirements and achieve shared goals The White House is seeking to renegotiate US CHIPS and Science Act awards and has signaled delays to some upcoming semiconductor disbursements, two sources familiar with the matter told reporters. The people, along with a third source, said that the new US administration is reviewing the projects awarded under the 2022 law, meant to boost US domestic semiconductor output with US$39 billion in subsidies. Washington plans to renegotiate some of the deals after assessing and changing current requirements, the sources said. The extent of the possible changes and how they would affect agreements already finalized was not immediately clear. It was not known